Removal of products from the Novel Food CBD List

The CTA notes that the list was reduced by 349 products. A senior member of the FSA team confirmed this was based on "lack of intel" provided by dossier holders or sufficient doubt about the proof provided, when challenged by the Novel Food team. There were issues with labelling whereby product content did not match what was on the label.

The CTA is investigating if there is a route for appeal and how this might work, as all regulators should:

•  inform dossiers holders about any products being removed from the list, in advance;
•  have an appeals process, should an error on either side have been made.

The entire industry is unable to move forward or innovate, and this situation needs to change. We recognise that there are judicial and legal routes that can be employed, however as a trade body we are seeking to mediate.